

# Madeleine T King

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1049226/madeleine-t-king-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132  
papers

4,386  
citations

33  
h-index

63  
g-index

143  
ext. papers

5,585  
ext. citations

4.5  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
132	Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 89-96	2.2	379
131	A point of minimal important difference (MID): a critique of terminology and methods. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2011</b> , 11, 171-84	2.2	345
130	Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 483-494	27.4	300
129	Time trade-off derived EQ-5D weights for Australia. <i>Value in Health</i> , <b>2011</b> , 14, 928-36	3.3	167
128	Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. <i>Quality of Life Research</i> , <b>2013</b> , 22, 1161-75	3.7	139
127	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 727-737	21.7	129
126	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , <b>2018</b> , 9, 353-367	2.9	129
125	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. <i>Lancet Oncology</i> , <b>2016</b> , 17, e510-e514	21.7	122
124	Deriving a preference-based measure for cancer using the EORTC QLQ-C30. <i>Value in Health</i> , <b>2011</b> , 14, 721-31	3.3	119
123	International comparisons in valuing EQ-5D health states: a review and analysis. <i>Value in Health</i> , <b>2009</b> , 12, 1194-200	3.3	114
122	A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses. <i>Supportive Care in Cancer</i> , <b>2010</b> , 18, 1241-62	3.9	112
121	Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 1793-8	7.5	107
120	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1753-60	3.9	99
119	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. <i>Lancet Oncology</i> , <b>2020</b> , 21, e83-e96	21.7	88
118	An Australian discrete choice experiment to value eq-5d health states. <i>Health Economics (United Kingdom)</i> , <b>2014</b> , 23, 729-42	2.4	82
117	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2808-19	7.5	81
116	Valuing SF-6D Health States Using a Discrete Choice Experiment. <i>Medical Decision Making</i> , <b>2014</b> , 34, 773-86	7.6	76

115	Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis. <i>Quality of Life Research</i> , <b>2016</b> , 25, 559-74	3.7	64
114	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. <i>BMJ Open</i> , <b>2016</b> , 6, e010938	3	58
113	Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. <i>PLoS ONE</i> , <b>2014</b> , 9, e110216	3.7	58
112	Symptom Clusters in Advanced Cancer Patients: An Empirical Comparison of Statistical Methods and the Impact on Quality of Life. <i>Journal of Pain and Symptom Management</i> , <b>2016</b> , 51, 88-98	4.8	53
111	Participation in psychosocial oncology and quality-of-life research: a systematic review. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e153-e165	21.7	52
110	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 225-238	4.4	45
109	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 223-33	5.1	44
108	Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. <i>PLoS ONE</i> , <b>2014</b> , 9, e110229	3.7	44
107	The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 8-16	7.5	44
106	Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 1170-1178	9.7	42
105	ProCare Trial: a phase II randomized controlled trial of shared care for follow-up of men with prostate cancer. <i>BJU International</i> , <b>2017</b> , 119, 381-389	5.6	42
104	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e459-e469	21.7	39
103	Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. <i>BMJ Open</i> , <b>2018</b> , 8, e019117	3	37
102	Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. <i>Oncologist</i> , <b>2015</b> , 20, 523-31	5.7	34
101	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , <b>2018</b> , 15, 624-630	2.2	34
100	Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. <i>Journal of Clinical Epidemiology</i> , <b>2010</b> , 63, 270-81	5.7	34
99	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1192-1201	21.7	33
98	A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 1129-1137	3.9	31

97	PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients. <i>Quality of Life Research</i> , <b>2018</b> , 27, 1357-1367	3.7	30
96	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. <i>Quality of Life Research</i> , <b>2016</b> , 25, 2457-2465	3.7	30
95	The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 100-7	5.7	30
94	Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 144-161	7.5	29
93	Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension. <i>Quality of Life Research</i> , <b>2017</b> , 26, 1427-1437	3.7	28
92	A Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) among cancer survivors. <i>Psychological Assessment</i> , <b>2013</b> , 25, 379-90	5.3	27
91	Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. <i>Patient Related Outcome Measures</i> , <b>2010</b> , 1, 119-26	2.9	27
90	Patient-reported outcomes in ductal carcinoma in situ: A systematic review. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 95-108	7.5	26
89	Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz037	4.6	25
88	The Impact of Cancer on Psychological and Social Outcomes. <i>Australian Psychologist</i> , <b>2016</b> , 51, 89-99	1.7	24
87	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. <i>Quality of Life Research</i> , <b>2018</b> , 27, 59-74	3.7	23
86	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	23
85	Making Sense of Variations in Prevalence Estimates of Depression in Cancer: A Co-Calibration of Commonly Used Depression Scales Using Rasch Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1203-11	7.3	23
84	Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 865-73	3.5	23
83	Validation and calibration of the SF-36 health transition question against an external criterion of clinical change in health status. <i>Quality of Life Research</i> , <b>2009</b> , 18, 637-45	3.7	23
82	Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?. <i>Medical Care</i> , <b>2019</b> , 57 Suppl 5 Suppl 1, S38-S45	3.1	23
81	Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. <i>European Journal of Cancer</i> , <b>2018</b> , 104, 169-181	7.5	23
80	Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 857-64	3.5	22

79	Measures of asthma control and quality of life: longitudinal data provide practical insights into their relative usefulness in different research contexts. <i>Quality of Life Research</i> , <b>2009</b> , 18, 301-12	3.7	19
78	Effects of publicity and a warning letter on illegal cigarette sales to minors. <i>Australian Journal of Public Health</i> , <b>1994</b> , 18, 39-42		19
77	U.K. utility weights for the EORTC QLU-C10D. <i>Health Economics (United Kingdom)</i> , <b>2019</b> , 28, 1385-1401	2.4	18
76	Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, 876-886	4	18
75	Patient-reported outcomes and experiences from the perspective of colorectal cancer survivors: meta-synthesis of qualitative studies. <i>Journal of Patient-Reported Outcomes</i> , <b>2020</b> , 4, 27	2.6	17
74	The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values. <i>Medical Journal of Australia</i> , <b>2019</b> , 210, 499-506	4	16
73	Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives. <i>Quality of Life Research</i> , <b>2015</b> , 24, 1317-25	3.7	16
72	Putting patients at the heart of health-care research. <i>Lancet, The</i> , <b>2015</b> , 385, 1073-4	4.0	16
71	Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. <i>BMJ, The</i> , <b>2020</b> , 371, m3503	5.9	16
70	Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 685-698	21.7	15
69	Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2015</b> , 59, 535-541	1.7	15
68	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 36-41	4.9	15
67	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. <i>Journal of Patient-Reported Outcomes</i> , <b>2017</b> , 1, 5	2.6	14
66	The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. <i>Contemporary Clinical Trials Communications</i> , <b>2018</b> , 9, 23-32	1.8	14
65	International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. <i>Quality of Life Research</i> , <b>2016</b> , 25, 359-362	3.7	14
64	Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 133, 623-631	4.8	14
63	Barriers to radiotherapy utilization: Consumer perceptions of issues influencing radiotherapy-related decisions. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, e489-e496	1.9	14
62	SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. <i>BMJ Open</i> , <b>2021</b> , 11, e045105	3	14

61	Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment. <i>Value in Health</i> , <b>2016</b> , 19, 1033-1038	3.3	14
60	A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. <i>Clinical Trials</i> , <b>2018</b> , 15, 95-106	2.2	14
59	Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States. <i>Value in Health</i> , <b>2018</b> , 21, 958-966	3.3	13
58	What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?. <i>Breast Cancer</i> , <b>2017</b> , 24, 720-729	3.4	12
57	Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). <i>Quality of Life Research</i> , <b>2018</b> , 27, 2581-2591	3.7	12
56	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. <i>Head and Neck</i> , <b>2020</b> , 42, 3141-3152	4.2	12
55	Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. <i>BMJ Open</i> , <b>2016</b> , 6, e012863	3	12
54	Patient-reported outcomes as predictors of survival in patients with bowel cancer: a systematic review. <i>Quality of Life Research</i> , <b>2019</b> , 28, 2871-2887	3.7	11
53	A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3095-3102	3.9	10
52	German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30. <i>Quality of Life Research</i> , <b>2019</b> , 28, 3197-3211	3.7	10
51	The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , <b>2019</b> , 4, 2381468319842532	1.5	9
50	Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, e381-e388	1.9	9
49	Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1209-18	3.9	8
48	Scientific rigour in psycho-oncology trials: why and how to avoid common statistical errors. <i>Psycho-Oncology</i> , <b>2013</b> , 22, 499-505	3.9	8
47	Psycho-social issues in long-term survivors of testicular cancer: Directions for future research. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2008</b> , 4, 125-131	1.9	8
46	Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 141-153	3.9	8
45	Implementing Patient-Reported Outcome Measures into Clinical Practice Across NSW: Mixed Methods Evaluation of the First Year. <i>Applied Research in Quality of Life</i> , <b>2021</b> , 16, 1265-1284	2.3	8
44	Treatment decision-making in ductal carcinoma in situ: A mixed methods systematic review of women's experiences and information needs. <i>Patient Education and Counseling</i> , <b>2017</b> , 100, 1654-1666	3.1	7

43	Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol. <i>BMJ Open</i> , <b>2018</b> , 8, e017282	3	6
42	Is quality of life a suitable measure of patient decision aid effectiveness? Sub-analysis of a Cochrane systematic review. <i>Quality of Life Research</i> , <b>2019</b> , 28, 593-607	3.7	6
41	Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 1061-1076	3.9	5
40	Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach. <i>Patient Related Outcome Measures</i> , <b>2014</b> , 5, 119-29	2.9	5
39	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 515-521	4.9	4
38	How is quality of life defined and assessed in published research?. <i>Quality of Life Research</i> , <b>2021</b> , 30, 2109-2124	3.7	4
37	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , <b>2021</b> , 24, 862-873	3.3	4
36	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1327-1336	1	4
35	Health-Related Quality of Life during Chemoradiation in Locally Advanced Rectal Cancer: Impacts and Ethnic Disparities. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
34	Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. <i>BMC Cancer</i> , <b>2021</b> , 21, 1083	4.8	3
33	International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: A qualitative study. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5475-5487	4.8	3
32	French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 191-202	3.4	3
31	Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. <i>Quality of Life Research</i> , <b>2021</b> , 30, 345-366	3.7	3
30	Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology. <i>Oral Oncology</i> , <b>2021</b> , 118, 105309	4.4	3
29	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 137, 31-44	5.7	3
28	Reduced quality of life in internet-panel controls. <i>Epidemiology</i> , <b>2013</b> , 24, 462-3	3.1	2
27	Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6012-6012	2.2	2
26	Health-Related Quality of Life in Cancer <b>2018</b> , 109-125		2

25	The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force. <i>Quality of Life Research</i> , <b>2021</b> , 1	3.7	2
24	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian	3.5	2
23	Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews.. <i>Quality of Life Research</i> , <b>2022</b> , 1	3.7	2
22	Impact of weight loss interventions on patient-reported outcomes in overweight and obese adults with type 2 diabetes: a systematic review. <i>Journal of Behavioral Medicine</i> , <b>2020</b> , 43, 873-891	3.6	1
21	An international study of multiracial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6002-6002	2.2	1
20	A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 142, 144-151	5.7	1
19	A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology	2.8	1
18	Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol. <i>JMIR Research Protocols</i> , <b>2017</b> , 6, e216	2	1
17	Recommendations for including or reviewing patient reported outcome endpoints in grant applications. <i>BMJ, The</i> , <b>2021</b> , 373, n1367	5.9	1
16	Trans Tasman Radiation Oncology Group Cancer Research: Phase III - Muscle Invasive Bladder Cancer trial (TROG 02.03): A moral dilemma. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2018</b> , 62, 668-670	1.7	1
15	Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 398-407	4.9	1
14	Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: a systematic review of qualitative studies. <i>Quality of Life Research</i> , <b>2021</b> , 1	3.7	1
13	Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D. <i>Quality of Life Research</i> , <b>2021</b> , 30, 2009-2019	3.7	1
12	Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.. <i>Lung Cancer</i> , <b>2022</b> , 167, 65-72	5.9	1
11	The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials.. <i>Clinical Trials</i> , <b>2022</b> , 17407745221077691	2.2	0
10	Apples to apples? Comparison of the measurement properties of hospital anxiety and depression-anxiety subscale (HADS-A), depression, anxiety and stress scale-anxiety subscale (DASS-A), and generalised anxiety disorder (GAD-7) scale in an oncology setting using Rasch analysis and diagnostic accuracy statistics. <i>Current Psychology</i> , <b>2020</b> , 1	1.4	0
9	United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument. <i>Medical Decision Making</i> , <b>2021</b> , 41, 485-501	2.5	0
8	Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 1085-1098	4.4	0



7	Improving the patient-reported outcome sections of clinical trial protocols: a mixed methods evaluation of educational workshops.. <i>Quality of Life Research</i> , <b>2022</b> , 1	3.7	o
6	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> ,	3.7	o
5	CLINICAL USE OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM CANCER CLINICAL TRIALS: PRELIMINARY RESULTS FROM A SURVEY OF ONCOLOGISTS. <i>Journal of Epidemiology and Community Health</i> , <b>2013</b> , 67, e2.17-e2	5.1	
4	Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7607-7607	2.2	
3	A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions. <i>Value in Health</i> , <b>2021</b> , 24, 1651-1659	3.3	
2	Expert perspective on Riddle and Dumenci's Commentary on finding meaning in patient-reported outcome change scores: a seemingly unquenchable thirst for understandingT. <i>Osteoarthritis and Cartilage</i> , <b>2022</b> ,	6.2	
1	The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights.. <i>Journal of Patient-Reported Outcomes</i> , <b>2022</b> , 6, 42	2.6	